TDMS Study 05120-03 Pathology Tables
INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a)
BENZYL ACETATE
NTP Experiment-Test: 05120-03 Report: PEIRPT05
Study Type: CHRONIC Date: 09/15/94
Route: DOSED FEED Time: 13:39:17
Facility: Southern Research Institute
Chemical CAS #: 140-11-4
Lock Date: None
Cage Range: All
Reasons For Removal: All
Removal Date Range: All
Treatment Groups: Include All
a Number of animals examined microscopically at site and number of animals with lesion
Page 1
NTP Experiment-Test: 05120-03 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC BENZYL ACETATE Date: 09/15/94
Route: DOSED FEED Time: 13:39:17
____________________________________________________________________________________________________________________________________
FISCHER 344 RATS FEMALE 0% 0.3% 0.6% 1.2%
____________________________________________________________________________________________________________________________________
DISPOSITION SUMMARY
Animals Initially in Study 60 60 60 60
Scheduled Sacrifice 10 10 10 10
Early Deaths
Moribund Sacrifice 18 17 13 19
Natural Death 2 3 3
Survivors
Terminal Sacrifice 30 30 37 28
Animals Examined Microscopically 60 60 60 60
____________________________________________________________________________________________________________________________________
ALIMENTARY SYSTEM
Intestine Large, Cecum (60) (60) (60) (60)
Intestine Small, Ileum (60) (60) (60) (60)
Intestine Small, Jejunum (59) (60) (60) (60)
Leiomyosarcoma 1 (2%)
Liver (60) (60) (60) (60)
Adenocarcinoma, Metastatic, Uncertain
Primary Site 1 (2%)
Cholangiocarcinoma 1 (2%)
Hepatocellular Carcinoma 1 (2%)
Hepatocellular Adenoma 2 (3%) 1 (2%) 1 (2%) 3 (5%)
Mesentery (11) (5) (7) (12)
Adenocarcinoma, Metastatic, Uncertain
Primary Site 1 (20%)
Adenocarcinoma, Metastatic, Uterus 1 (9%)
Liposarcoma, Metastatic, Kidney 1 (8%)
Pancreas (60) (60) (60) (60)
Adenocarcinoma, Metastatic, Uncertain
Primary Site 1 (2%)
Salivary Glands (60) (60) (60) (60)
Adenoma 1 (2%)
Stomach, Forestomach (60) (60) (60) (60)
Stomach, Glandular (60) (60) (60) (60)
Tongue (60) (60) (60) (60)
Squamous Cell Carcinoma 1 (2%)
Squamous Cell Papilloma 1 (2%)
Tooth (1) (3) (1)
Peridontal Tissue, Adenocarcinoma,
Metastatic, Uncertain Primary Site 1 (33%)
____________________________________________________________________________________________________________________________________
Page 2
NTP Experiment-Test: 05120-03 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC BENZYL ACETATE Date: 09/15/94
Route: DOSED FEED Time: 13:39:17
____________________________________________________________________________________________________________________________________
FISCHER 344 RATS FEMALE 0% 0.3% 0.6% 1.2%
____________________________________________________________________________________________________________________________________
CARDIOVASCULAR SYSTEM
Heart (60) (60) (60) (60)
Pheochromocytoma Malignant, Metastatic,
Adrenal Gland 1 (2%)
____________________________________________________________________________________________________________________________________
ENDOCRINE SYSTEM
Adrenal Gland, Cortex (60) (60) (60) (60)
Adenocarcinoma, Metastatic, Uncertain
Primary Site 1 (2%)
Adenoma 3 (5%) 2 (3%) 1 (2%) 1 (2%)
Adrenal Gland, Medulla (60) (60) (60) (60)
Ganglioneuroma 1 (2%)
Pheochromocytoma Malignant 1 (2%) 1 (2%) 1 (2%)
Pheochromocytoma Benign 1 (2%) 5 (8%) 1 (2%)
Islets, Pancreatic (60) (60) (60) (60)
Adenoma 3 (5%) 1 (2%)
Parathyroid Gland (58) (60) (59) (57)
Adenoma 1 (2%)
Pituitary Gland (60) (60) (60) (60)
Pars Distalis, Adenoma 38 (63%) 33 (55%) 31 (52%) 33 (55%)
Pars Distalis, Adenoma, Multiple, Two 1 (2%)
Pars Distalis, Carcinoma 1 (2%) 1 (2%)
Pars Intermedia, Adenoma 1 (2%) 1 (2%)
Pars Intermedia, Carcinoma 1 (2%)
Thyroid Gland (60) (60) (60) (59)
C-Cell, Adenoma 4 (7%) 4 (7%) 9 (15%) 5 (8%)
C-Cell, Carcinoma 2 (3%)
Follicular Cell, Adenoma 1 (2%) 1 (2%)
Follicular Cell, Carcinoma 1 (2%) 1 (2%)
____________________________________________________________________________________________________________________________________
GENERAL BODY SYSTEM
None
____________________________________________________________________________________________________________________________________
GENITAL SYSTEM
Clitoral Gland (60) (60) (60) (59)
Adenoma 1 (2%) 1 (2%) 1 (2%)
Carcinoma 1 (2%) 1 (2%)
Sarcoma 1 (2%)
Squamous Cell Papilloma 1 (2%)
Ovary (60) (60) (60) (59)
Adenocarcinoma, Metastatic, Uncertain
Page 3
NTP Experiment-Test: 05120-03 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC BENZYL ACETATE Date: 09/15/94
Route: DOSED FEED Time: 13:39:17
____________________________________________________________________________________________________________________________________
FISCHER 344 RATS FEMALE 0% 0.3% 0.6% 1.2%
____________________________________________________________________________________________________________________________________
GENITAL SYSTEM - cont
Primary Site 1 (2%)
Adenocarcinoma, Metastatic, Uterus 1 (2%)
Uterus (60) (60) (60) (60)
Adenocarcinoma 1 (2%) 1 (2%)
Adenoma 2 (3%)
Sarcoma 1 (2%)
Schwannoma Malignant 1 (2%)
Endometrium, Polyp Stromal 15 (25%) 16 (27%) 4 (7%) 10 (17%)
Endometrium, Polyp Stromal, Multiple 2 (3%)
Endometrium, Sarcoma Stromal 1 (2%) 2 (3%)
Endothelium, Polyp Stromal 1 (2%)
Vagina (2) (1) (2) (2)
Basal Cell Adenoma 1 (50%)
____________________________________________________________________________________________________________________________________
HEMATOPOIETIC SYSTEM
Bone Marrow (60) (60) (60) (60)
Adenocarcinoma, Metastatic, Uncertain
Primary Site 1 (2%)
Lymph Node (60) (60) (60) (60)
Lymph Node, Mandibular (60) (60) (60) (59)
Lymph Node, Mesenteric (60) (60) (60) (59)
Spleen (60) (60) (60) (60)
Thymus (59) (54) (59) (60)
Leiomyoma 1 (2%)
Epithelial Cell, Thymoma Benign 1 (2%)
____________________________________________________________________________________________________________________________________
INTEGUMENTARY SYSTEM
Mammary Gland (60) (60) (60) (60)
Adenocarcinoma 1 (2%) 1 (2%)
Adenoma 1 (2%)
Fibroadenoma 10 (17%) 13 (22%) 10 (17%) 16 (27%)
Fibroadenoma, Multiple, Two 2 (3%) 4 (7%) 2 (3%) 1 (2%)
Fibroadenoma, Multiple, Three 1 (2%)
Fibroma 1 (2%)
Skin (60) (60) (60) (60)
Subcutaneous Tissue, Fibroma 1 (2%) 2 (3%)
____________________________________________________________________________________________________________________________________
Page 4
NTP Experiment-Test: 05120-03 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC BENZYL ACETATE Date: 09/15/94
Route: DOSED FEED Time: 13:39:17
____________________________________________________________________________________________________________________________________
FISCHER 344 RATS FEMALE 0% 0.3% 0.6% 1.2%
____________________________________________________________________________________________________________________________________
MUSCULOSKELETAL SYSTEM
Skeletal Muscle (60) (60) (60) (60)
Adenocarcinoma, Metastatic, Uncertain
Primary Site 1 (2%)
Adenocarcinoma, Metastatic, Uterus 1 (2%)
____________________________________________________________________________________________________________________________________
NERVOUS SYSTEM
Brain (60) (60) (60) (60)
Astrocytoma Malignant 1 (2%)
Glioma Malignant 1 (2%) 1 (2%)
Peripheral Nerve (1) (1)
____________________________________________________________________________________________________________________________________
RESPIRATORY SYSTEM
Lung (60) (60) (60) (60)
Adenocarcinoma 1 (2%)
Adenocarcinoma, Metastatic, Uncertain
Primary Site 1 (2%)
Adenocarcinoma, Metastatic, Uterus 1 (2%)
Carcinoma, Metastatic, Zymbal's Gland 1 (2%)
Pheochromocytoma Malignant, Metastatic,
Adrenal Gland 1 (2%)
Mediastinum, Adenocarcinoma, Metastatic,
Uncertain Primary Site 1 (2%)
Nose (60) (60) (60) (60)
Adenocarcinoma, Metastatic, Uncertain
Primary Site 1 (2%)
____________________________________________________________________________________________________________________________________
SPECIAL SENSES SYSTEM
Harderian Gland (1) (1) (1)
Zymbal's Gland (1) (3)
Carcinoma 1 (100%) 2 (67%)
____________________________________________________________________________________________________________________________________
URINARY SYSTEM
Kidney (60) (60) (60) (60)
Adenocarcinoma, Metastatic, Uncertain
Primary Site 1 (2%)
Adenocarcinoma, Metastatic, Uterus 1 (2%)
Liposarcoma 1 (2%)
Urinary Bladder (60) (60) (60) (60)
Page 5
NTP Experiment-Test: 05120-03 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC BENZYL ACETATE Date: 09/15/94
Route: DOSED FEED Time: 13:39:17
____________________________________________________________________________________________________________________________________
FISCHER 344 RATS FEMALE 0% 0.3% 0.6% 1.2%
____________________________________________________________________________________________________________________________________
URINARY SYSTEM - cont
Adenocarcinoma, Metastatic, Uterus 1 (2%)
Transitional Epithelium, Papilloma 1 (2%)
____________________________________________________________________________________________________________________________________
SYSTEMIC LESIONS
Multiple Organs *(60) *(60) *(60) *(60)
Leukemia Mononuclear 9 (15%) 6 (10%) 12 (20%) 12 (20%)
Mesothelioma Benign 1 (2%)
____________________________________________________________________________________________________________________________________
* Number of animals with any tissue examined microscopically
Page 6
NTP Experiment-Test: 05120-03 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC BENZYL ACETATE Date: 09/15/94
Route: DOSED FEED Time: 13:39:17
____________________________________________________________________________________________________________________________________
FISCHER 344 RATS FEMALE 0% 0.3% 0.6% 1.2%
____________________________________________________________________________________________________________________________________
TUMOR SUMMARY
Total Animals with Primary Neoplasms (b) 53 50 45 52
Total Primary Neoplasms 101 100 88 98
Total Animals with Benign Neoplasms 47 45 39 47
Total Benign Neoplasms 84 86 67 77
Total Animals with Malignant Neoplasms 15 13 18 18
Total Malignant Neoplasms 17 14 21 21
Total Animals with Metastatic Neoplasms 2 2 1
Total Metastatic Neoplasm 8 13 1
Total Animals with Malignant Neoplasms 1
Uncertain Primary Site
Total Animals with Neoplasms Uncertain-
Benign or Malignant
Total Uncertain Neoplasms
____________________________________________________________________________________________________________________________________
a Number of animals examined microscopically at site and number of animals with lesion
b Primary tumors: all tumors except metastatic tumors
Page 7
NTP Experiment-Test: 05120-03 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC BENZYL ACETATE Date: 09/15/94
Route: DOSED FEED Time: 13:39:17
____________________________________________________________________________________________________________________________________
FISCHER 344 RATS MALE 0% 0.3% 0.6% 1.2%
____________________________________________________________________________________________________________________________________
DISPOSITION SUMMARY
Animals Initially in Study 60 60 60 60
Scheduled Sacrifice 10 10 10 10
Early Deaths
Moribund Sacrifice 20 12 16 14
Natural Death 3 4 4 3
Survivors
Terminal Sacrifice 27 34 30 33
Animals Examined Microscopically 60 60 60 60
____________________________________________________________________________________________________________________________________
ALIMENTARY SYSTEM
Intestine Large, Cecum (60) (60) (60) (59)
Intestine Large, Colon (60) (60) (59) (59)
Adenocarcinoma 1 (2%)
Intestine Small, Ileum (59) (60) (60) (59)
Intestine Small, Jejunum (59) (60) (60) (58)
Liver (60) (60) (60) (60)
Adenocarcinoma, Metastatic, Intestine Large 1 (2%)
Hepatocellular Carcinoma 1 (2%)
Hepatocellular Adenoma 5 (8%) 4 (7%) 3 (5%) 3 (5%)
Hepatocellular Adenoma, Multiple, Two 1 (2%)
Hepatocellular Adenoma, Multiple, Three 1 (2%)
Hepatocellular Adenoma, Multiple, Four 1 (2%)
Sarcoma, Metastatic, Uncertain Primary Site 1 (2%)
Mesentery (17) (16) (13) (11)
Adenocarcinoma, Metastatic, Intestine Large 1 (6%)
Lipoma 1 (9%)
Sarcoma, Metastatic, Uncertain Primary Site 1 (8%)
Pancreas (60) (60) (60) (59)
Adenocarcinoma, Metastatic, Intestine Large 1 (2%)
Acinar Cell, Adenoma 1 (2%) 3 (5%) 1 (2%)
Acinar Cell, Adenoma, Multiple 2 (3%)
Pharynx (2) (1)
Palate, Squamous Cell Carcinoma 2 (100%)
Palate, Squamous Cell Papilloma 1 (100%)
Salivary Glands (60) (60) (60) (59)
Adenoma 1 (2%)
Sarcoma, Metastatic, Uncertain Primary Site 1 (2%)
Stomach, Forestomach (60) (60) (60) (60)
Basal Cell Adenoma 1 (2%)
Squamous Cell Papilloma 1 (2%)
Stomach, Glandular (60) (60) (60) (60)
Page 8
NTP Experiment-Test: 05120-03 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC BENZYL ACETATE Date: 09/15/94
Route: DOSED FEED Time: 13:39:17
____________________________________________________________________________________________________________________________________
FISCHER 344 RATS MALE 0% 0.3% 0.6% 1.2%
____________________________________________________________________________________________________________________________________
ALIMENTARY SYSTEM - cont
Tongue (60) (60) (59) (60)
Squamous Cell Carcinoma 1 (2%)
____________________________________________________________________________________________________________________________________
CARDIOVASCULAR SYSTEM
Heart (60) (60) (60) (60)
Adenocarcinoma, Metastatic 1 (2%)
____________________________________________________________________________________________________________________________________
ENDOCRINE SYSTEM
Adrenal Gland, Cortex (60) (60) (60) (60)
Adenoma 1 (2%) 2 (3%)
Adrenal Gland, Medulla (60) (60) (60) (60)
Pheochromocytoma Malignant 1 (2%) 2 (3%) 2 (3%) 2 (3%)
Pheochromocytoma Complex 1 (2%) 2 (3%)
Pheochromocytoma Benign 16 (27%) 8 (13%) 15 (25%) 13 (22%)
Bilateral, Pheochromocytoma Benign 1 (2%) 4 (7%) 1 (2%) 1 (2%)
Islets, Pancreatic (60) (60) (60) (60)
Adenoma 2 (3%) 1 (2%) 1 (2%)
Carcinoma 1 (2%)
Pituitary Gland (59) (60) (59) (58)
Pars Distalis, Adenoma 11 (19%) 9 (15%) 10 (17%) 6 (10%)
Thyroid Gland (60) (59) (60) (58)
C-Cell, Adenoma 9 (15%) 4 (7%) 7 (12%) 7 (12%)
C-Cell, Carcinoma 1 (2%) 1 (2%) 5 (8%) 1 (2%)
____________________________________________________________________________________________________________________________________
GENERAL BODY SYSTEM
Tissue NOS (1) (1) (2) (1)
Cranial, Sarcoma, Metastatic, Uncertain
Primary Site 1 (100%)
Pelvic, Sarcoma, Metastatic, Uncertain
Primary Site 1 (50%)
____________________________________________________________________________________________________________________________________
GENITAL SYSTEM
Epididymis (60) (60) (60) (60)
Preputial Gland (60) (60) (60) (60)
Adenoma 3 (5%) 2 (3%) 3 (5%) 2 (3%)
Carcinoma 1 (2%) 1 (2%)
Prostate (60) (60) (60) (60)
Adenocarcinoma, Metastatic, Intestine Large 1 (2%)
Seminal Vesicle (60) (60) (60) (60)
Page 9
NTP Experiment-Test: 05120-03 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC BENZYL ACETATE Date: 09/15/94
Route: DOSED FEED Time: 13:39:17
____________________________________________________________________________________________________________________________________
FISCHER 344 RATS MALE 0% 0.3% 0.6% 1.2%
____________________________________________________________________________________________________________________________________
GENITAL SYSTEM - cont
Adenocarcinoma, Metastatic, Intestine Large 1 (2%)
Testes (60) (60) (60) (60)
Bilateral, Interstitial Cell, Adenoma 54 (90%) 56 (93%) 55 (92%) 54 (90%)
Interstitial Cell, Adenoma 3 (5%) 2 (3%) 5 (8%) 5 (8%)
____________________________________________________________________________________________________________________________________
HEMATOPOIETIC SYSTEM
Bone Marrow (60) (60) (60) (59)
Lymph Node (60) (60) (60) (59)
Deep Cervical, Carcinoma, Metastatic,
Zymbal's Gland 1 (2%)
Mediastinal, Adenocarcinoma, Metastatic,
Intestine Large 1 (2%)
Renal, Adenocarcinoma, Metastatic, Intestine
Large 1 (2%)
Lymph Node, Mandibular (60) (59) (60) (58)
Carcinoma, Metastatic, Zymbal's Gland 1 (2%)
Sarcoma, Metastatic, Uncertain Primary Site 1 (2%)
Lymph Node, Mesenteric (60) (60) (58) (59)
Adenocarcinoma, Metastatic, Intestine Large 1 (2%)
Spleen (60) (60) (60) (60)
Fibroma 1 (2%)
Osteosarcoma, Metastatic, Bone 1 (2%)
Thymus (58) (58) (58) (55)
Adenocarcinoma, Metastatic 1 (2%)
Epithelial Cell, Thymoma Benign 1 (2%) 1 (2%)
____________________________________________________________________________________________________________________________________
INTEGUMENTARY SYSTEM
Mammary Gland (58) (58) (58) (60)
Fibroadenoma 4 (7%) 2 (3%) 1 (2%)
Skin (60) (60) (60) (60)
Basal Cell Carcinoma 1 (2%)
Histiocytic Sarcoma 1 (2%)
Keratoacanthoma 5 (8%) 1 (2%)
Schwannoma Malignant, Metastatic, Skeletal
Muscle 1 (2%)
Squamous Cell Papilloma 1 (2%)
Subcutaneous Tissue, Fibroma 4 (7%) 2 (3%) 3 (5%) 3 (5%)
Subcutaneous Tissue, Fibrosarcoma 1 (2%) 2 (3%)
Subcutaneous Tissue, Leiomyoma 1 (2%)
Subcutaneous Tissue, Lipoma 1 (2%)
Subcutaneous Tissue, Sarcoma 1 (2%)
Subcutaneous Tissue, Sarcoma, Metastatic,
Uncertain Primary Site 1 (2%)
Page 10
NTP Experiment-Test: 05120-03 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC BENZYL ACETATE Date: 09/15/94
Route: DOSED FEED Time: 13:39:17
____________________________________________________________________________________________________________________________________
FISCHER 344 RATS MALE 0% 0.3% 0.6% 1.2%
____________________________________________________________________________________________________________________________________
____________________________________________________________________________________________________________________________________
MUSCULOSKELETAL SYSTEM
Bone (60) (60) (60) (60)
Osteosarcoma 1 (2%)
Skeletal Muscle (60) (60) (60) (60)
Adenocarcinoma, Metastatic, Intestine Large 1 (2%)
Sarcoma, Metastatic, Uncertain Primary Site 1 (2%)
Schwannoma Malignant 1 (2%)
____________________________________________________________________________________________________________________________________
NERVOUS SYSTEM
Brain (60) (60) (60) (60)
Glioma Malignant 1 (2%)
Glioma NOS 1 (2%)
Oligodendroglioma Malignant 1 (2%)
____________________________________________________________________________________________________________________________________
RESPIRATORY SYSTEM
Lung (60) (60) (60) (60)
Adenocarcinoma, Metastatic, Intestine Large 1 (2%)
Alveolar/Bronchiolar Adenoma 2 (3%) 2 (3%) 1 (2%)
Alveolar/Bronchiolar Adenoma, Multiple, Four 1 (2%)
Osteosarcoma, Metastatic, Bone 1 (2%)
Squamous Cell Carcinoma, Metastatic,
Uncertain Primary Site 1 (2%)
Mediastinum, Adenocarcinoma, Metastatic,
Intestine Large 1 (2%)
Nose (60) (60) (60) (60)
Mucosa, Squamous Cell Carcinoma 1 (2%) 1 (2%) 1 (2%)
Vomeronasal Organ, Carcinoma 1 (2%)
____________________________________________________________________________________________________________________________________
SPECIAL SENSES SYSTEM
Zymbal's Gland (1) (1) (2)
Carcinoma 1 (100%) 1 (100%) 1 (50%)
____________________________________________________________________________________________________________________________________
URINARY SYSTEM
Kidney (60) (60) (60) (60)
Adenocarcinoma, Metastatic, Intestine Large 1 (2%)
Lipoma 1 (2%)
Squamous Cell Carcinoma, Metastatic,
Page 11
NTP Experiment-Test: 05120-03 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC BENZYL ACETATE Date: 09/15/94
Route: DOSED FEED Time: 13:39:17
____________________________________________________________________________________________________________________________________
FISCHER 344 RATS MALE 0% 0.3% 0.6% 1.2%
____________________________________________________________________________________________________________________________________
URINARY SYSTEM - cont
Uncertain Primary Site 1 (2%)
Renal Tubule, Adenoma 1 (2%)
Urinary Bladder (60) (60) (60) (60)
Squamous Cell Papilloma 1 (2%)
____________________________________________________________________________________________________________________________________
SYSTEMIC LESIONS
Multiple Organs *(60) *(60) *(60) *(60)
Histiocytic Sarcoma 1 (2%)
Leukemia Mononuclear 16 (27%) 19 (32%) 18 (30%) 15 (25%)
Mesothelioma Benign 1 (2%) 2 (3%) 1 (2%)
Mesothelioma Malignant 1 (2%) 1 (2%)
____________________________________________________________________________________________________________________________________
* Number of animals with any tissue examined microscopically
Page 12
NTP Experiment-Test: 05120-03 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC BENZYL ACETATE Date: 09/15/94
Route: DOSED FEED Time: 13:39:17
____________________________________________________________________________________________________________________________________
FISCHER 344 RATS MALE 0% 0.3% 0.6% 1.2%
____________________________________________________________________________________________________________________________________
TUMOR SUMMARY
Total Animals with Primary Neoplasms (b) 60 59 60 60
Total Primary Neoplasms 148 140 144 129
Total Animals with Benign Neoplasms 60 59 60 60
Total Benign Neoplasms 124 106 113 104
Total Animals with Malignant Neoplasms 20 29 28 22
Total Malignant Neoplasms 24 33 31 25
Total Animals with Metastatic Neoplasms 1 2 1 3
Total Metastatic Neoplasm 1 16 3 9
Total Animals with Malignant Neoplasms 1 2
Uncertain Primary Site
Total Animals with Neoplasms Uncertain-
Benign or Malignant 1
Total Uncertain Neoplasms 1
____________________________________________________________________________________________________________________________________
a Number of animals examined microscopically at site and number of animals with lesion
b Primary tumors: all tumors except metastatic tumors
Page 13
------------------------------------------------------------
---------- END OF REPORT ----------
------------------------------------------------------------